Personal Profile
His major clinical and research interest is hepatitis C infection. Dr Ryder was a major contributor to The Trent HCV Cohort Study which described the epidemiology and natural history of hepatitis C virus infection in the UK. This data was used in the Department of Health Hepatitis C Strategy for England and Wales (2002) and has been quoted in all the annual reports on Hepatitis C from the Department of Health. This work has informed national policy on hepatitis C management. He has also contributed to national and European guidelines for the treatment of hepatitis C. He was the main author of the national guidelines for the management of primary liver cancer.
Dr Ryder was the national lead for the Hepatology Clinical Research Network and has had a significant role in coordinating clinical trials of new therapies for hepatitis C and ensuring as many people as possible from the UK with hepatitis C have access to trial therapies.
Dr Ryder is Hepatology Vice President of the British Society of Gastroenterology having been a member of Liver section for 4 years and chair of the liver section for the two. He contributed to the Lancet commission on liver disease, a group involving clinicians, patient groups and charities to help advance liver services for people living with liver disease in the UK.